4.8 Article

Aurora-A kinase oncogenic signaling mediates TGF-beta-induced triple-negative breast cancer plasticity and chemoresistance

Journal

ONCOGENE
Volume 40, Issue 14, Pages 2509-2523

Publisher

SPRINGERNATURE
DOI: 10.1038/s41388-021-01711-x

Keywords

-

Funding

  1. Intramural RECDA
  2. Nan Sawyer Award
  3. Randy Shaver Cancer Research and Community Fund
  4. Mayo Clinic Breast Cancer Specialized Program of Research Excellence (SPORE) NIH [CA116201]
  5. Mayo Clinic Breast Cancer SPORE NIH [CA116201]
  6. Prospect Creek Foundation
  7. Mayo Clinic Comprehensive Cancer Center
  8. [NCI-CA214893]
  9. [NCI-CA72836]

Ask authors/readers for more resources

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, with progression linked to the enrichment of breast tumor-initiating cells (BTICs) and chemoresistance. The study revealed that AURKA kinase plays a critical role in mediating TGF-beta-induced TNBC plasticity, chemoresistance, and tumor progression.
Triple-negative breast cancer (TNBCs) account for 15-20% of all breast cancers and represent the most aggressive subtype of this malignancy. Early tumor relapse and progression are linked to the enrichment of a sub-fraction of cancer cells, termed breast tumor-initiating cells (BTICs), that undergo epithelial to mesenchymal transition (EMT) and typically exhibit a basal-like CD44(high)/CD24(low) and/or ALDH1(high) phenotype with critical cancer stem-like features such as high self-renewal capacity and intrinsic (de novo) resistance to standard of care chemotherapy. One of the major mechanisms responsible for the intrinsic drug resistance of BTICs is their high ALDH1 activity leading to inhibition of chemotherapy-induced apoptosis. In this study, we demonstrated that aurora-A kinase (AURKA) is required to mediate TGF-beta-induced expression of the SNAI1 gene, enrichment of ALDH1(high) BTICs, self-renewal capacity, and chemoresistance in TNBC experimental models. Significantly, the combination of docetaxel (DTX) with dual TGF-beta and AURKA pharmacologic targeting impaired tumor relapse and the emergence of distant metastasis. We also showed in unique chemoresistant TNBC cells isolated from patient-derived TNBC brain metastasis that dual TGF-beta and AURKA pharmacologic targeting reversed cancer plasticity and enhanced the sensitivity of TNBC cells to DTX-based-chemotherapy. Taken together, these findings reveal for the first time the critical role of AURKA oncogenic signaling in mediating TGF-beta-induced TNBC plasticity, chemoresistance, and tumor progression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available